FRANKLIN LAKES, N.J.,
April 19, 2018
/PRNewswire/ -- BD (Becton, Dickinson and Company)
(NYSE: BDX), a leading global medical technology company, today
introduced several new informatics and automation solutions for
clinical laboratories, which may play a critical role in the fight
against infectious diseases and antimicrobial resistance. The new
molecular, microbiology and software solutions will be showcased at
the upcoming European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID) in Madrid,
Spain.
The company announced the plan for the commercial availability
of BD Synapsys™ microbiology informatics solution, which provides
laboratories with secure connectivity across instruments and
locations. The new easy-to-use, browser-based application will help
streamline workflows, automate manual processes, and facilitate
on-demand actionable insights. Together these capabilities will
enable laboratories to improve productivity, simplify compliance,
and ultimately get results to clinicians more efficiently.
The BD Synapsys solution will enable on-demand access to data
and actionable insights, initially supporting BD
BACTEC™ FX systems, BD Kiestra™
solutions, and in the United
States BD VeritorTM Plus systems, with plans to
include other BD clinical microbiology instruments in the future.
This solution helps laboratories and hospitals meet cybersecurity
and data privacy standards. The BD Synapsys solution will soon be
available in the United States and
will be offered in Western Europe
and Canada.
"BD understands our lab needs an advanced informatics solution
that supports integrated workflow across lab instruments, with
access to data across all systems to better utilize our resources,
reduce turnaround times and error rates, and show efficiency data
in order to maximize the usage of our instrumentation to ultimately
allow us to better serve our physicians and patients," said
Alanna Emrick, Microbiology Manager
at UMC Health System.
Also to be unveiled at the BD booth at ECCMID:
- BD COR™ system is an all new high-throughput
molecular platform designed to support a menu of clinically
differentiated assays for women's health, sexually transmitted
infections and gastrointestinal (GI) applications. The automated
system integrates the pre-analytical and analytical steps needed to
process samples and provide actionable results, while reducing
hands on time for laboratory staff and reducing the potential for
manual errors. The BD COR system will be offered in Western Europe beginning in mid-2019 following
required regulatory authorization.
- BD Kiestra ID/AST modules will be new additions to the BD
Kiestra solution that automate the processing steps for bacterial
identification and antibiotic susceptibility testing using the BD
Bruker MALDI and BD Phoenix™ systems. These unique laboratory
automation solutions use a single organism to ensure that the same
bacteria is used in both tests. As with other BD Kiestra modules,
the ID/AST modules will drive efficiency in the lab, reduce
hands-on time, eliminate errors, and ultimately help clinicians
make timely patient management decisions. Upon receiving applicable
regulatory authorizations, the BD Kiestra ID module will be offered
in early 2019 and the ID/AST module will be available in mid-2019,
initially in Europe and
Canada. Availability in the U.S.
and other regions will follow after regulatory authorizations are
secured.
The company also highlighted recently launched CE-IVD marked
panels for the BD MAX™ system. The panels are not
available in the United States. These include:
- BD MAX enteric viral panel, available in two configurations.
The panels can identify norovirus, rotavirus, adenovirus, sapovirus
and human astrovirus, all of which are central to the diagnosis of
infectious diarrhea.
- BD MAX Check-Points CPO assay, was developed in conjunction
with Check-Points Health B.V. This test provides detection of the
five most common carbapenemase genes in approximately 2.5 hours,
allowing for the rapid identification of patients colonized with
these organisms so that proper infection control measures can be
implemented.
"We aim to bring our customers the most comprehensive portfolio
of high-quality diagnostic tools, because we understand that
important medical decisions about patient management and treatment
rely on our products," said Dave
Hickey, president, Diagnostic Systems at BD. "These
innovative new solutions will enable more robust processing of
clinical samples, and faster, more comprehensive reporting of
results back to clinicians."
BD invites customers and media to join us in ECCMID booth #13 on
April 21 at 3:30 p.m. for an innovation celebration with
Dave Hickey to learn more about BD's
clinical microbiology solutions.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help improve patient
outcomes, improve the safety and efficiency of clinicians' care
delivery process, enable laboratory scientists to better diagnose
disease and advance researchers' capabilities to develop the next
generation of diagnostics and therapeutics. BD has a presence in
virtually every country and partners with organizations around the
world to address some of the most challenging global health issues.
By working in close collaboration with customers, BD can help
enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. In 2017, BD welcomed C. R.
Bard and its products into the BD family. For more information on
BD, please visit bd.com.
Forward Looking Statements
This press release contains certain forward-looking statements (as
defined under Federal securities laws) regarding certain BD product
introductions. Forward looking statements may be identified by use
of words such as "will", "plan" or other words of similar meaning.
All such statements are based upon the current expectations
of BD and involve a number of business risks and uncertainties that
could cause actual results to differ materially from anticipated
results described, implied or projected in any forward-looking
statement, including, without limitation, issues relating to
regulatory compliance, competition, rapid or unexpected changes in
technologies, uncertainties inherent in product development and
commercialization, and the ability of our products to gain market
acceptance. We do not intend to update any forward-looking
statements to reflect events or circumstances after the date hereof
except as required by applicable laws or regulations.
Contacts:
|
|
Gwen
Gordon
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.812.3724
|
201.847.5378
|
gwen.gordon@bd.com
|
monique_dolecki@bd.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/bd-unveils-suite-of-diagnostic-informatics-and-automation-innovations-300632594.html
SOURCE BD (Becton, Dickinson and Company)